These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
200 related articles for article (PubMed ID: 35989458)
21. High single-drug activity of nelarabine in relapsed T-lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Gökbuget N; Basara N; Baurmann H; Beck J; Brüggemann M; Diedrich H; Güldenzoph B; Hartung G; Horst HA; Hüttmann A; Kobbe G; Naumann R; Ratei R; Reichle A; Serve H; Stelljes M; Viardot A; Wattad M; Hoelzer D Blood; 2011 Sep; 118(13):3504-11. PubMed ID: 21715318 [TBL] [Abstract][Full Text] [Related]
22. Temsirolimus combined with cyclophosphamide and etoposide for pediatric patients with relapsed/refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium trial (TACL 2014-001). Tasian SK; Silverman LB; Whitlock JA; Sposto R; Loftus JP; Schafer ES; Schultz KR; Hutchinson RJ; Gaynon PS; Orgel E; Bateman CM; Cooper TM; Laetsch TW; Sulis ML; Chi YY; Malvar J; Wayne AS; Rheingold SR Haematologica; 2022 Oct; 107(10):2295-2303. PubMed ID: 35112552 [TBL] [Abstract][Full Text] [Related]
23. A Phase I Study of Clofarabine With Multiagent Chemotherapy in Childhood High Risk Relapse of Acute Lymphoblastic Leukemia (VANDEVOL Study of the French SFCE Acute Leukemia Committee). Nelken B; Cave H; Leverger G; Galambrun C; Plat G; Schmitt C; Thomas C; Vérité C; Brethon B; Gandemer V; Bertrand Y; Baruchel A; Rohrlich P Pediatr Blood Cancer; 2016 Feb; 63(2):270-5. PubMed ID: 26376115 [TBL] [Abstract][Full Text] [Related]
25. Nelarabine combination therapy for relapsed or refractory T-cell acute lymphoblastic lymphoma/leukemia. Shimony S; Liu Y; Valtis YK; Paolino JD; Place AE; Brunner AM; Weeks LD; Silverman LB; Vrooman LM; Neuberg DS; Stone RM; DeAngelo DJ; Luskin MR Blood Adv; 2023 Apr; 7(7):1092-1102. PubMed ID: 36508268 [TBL] [Abstract][Full Text] [Related]
26. Safety of nelarabine in adults with relapsed or refractory T-cell acute lymphoblastic leukemia/lymphoma. Candoni A; Lazzarotto D; Petruzzellis G Expert Opin Drug Saf; 2021 Jul; 20(7):751-756. PubMed ID: 33866913 [TBL] [Abstract][Full Text] [Related]
27. Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1). Raetz EA; Teachey DT; Minard C; Liu X; Norris RE; Denic KZ; Reid J; Evensen NA; Gore L; Fox E; Loh ML; Weigel BJ; Carroll WL Pediatr Blood Cancer; 2023 Nov; 70(11):e30609. PubMed ID: 37553297 [TBL] [Abstract][Full Text] [Related]
28. Safety and efficacy of nelarabine in children and young adults with relapsed or refractory T-lineage acute lymphoblastic leukaemia or T-lineage lymphoblastic lymphoma: results of a phase 4 study. Zwaan CM; Kowalczyk J; Schmitt C; Bielorai B; Russo MW; Woessner M; Ranganathan S; Leverger G Br J Haematol; 2017 Oct; 179(2):284-293. PubMed ID: 28771663 [TBL] [Abstract][Full Text] [Related]
29. Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. DeAngelo DJ; Yu D; Johnson JL; Coutre SE; Stone RM; Stopeck AT; Gockerman JP; Mitchell BS; Appelbaum FR; Larson RA Blood; 2007 Jun; 109(12):5136-42. PubMed ID: 17344466 [TBL] [Abstract][Full Text] [Related]
30. Safe integration of nelarabine into intensive chemotherapy in newly diagnosed T-cell acute lymphoblastic leukemia: Children's Oncology Group Study AALL0434. Winter SS; Dunsmore KP; Devidas M; Eisenberg N; Asselin BL; Wood BL; Leonard Rn MS; Murphy J; Gastier-Foster JM; Carroll AJ; Heerema NA; Loh ML; Raetz EA; Winick NJ; Carroll WL; Hunger SP Pediatr Blood Cancer; 2015 Jul; 62(7):1176-83. PubMed ID: 25755211 [TBL] [Abstract][Full Text] [Related]
31. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia: literature review and own experience. Dyakonova YY; Bydanov OI; Popov AM; Olshanskaya YV; Boichenko EG; Aleynikova OV; Maschan MA; Shelikhova LN; Litvinov DV; Khachatryan LA; Ponomareva NI; Fechina LG; Novichkova GA; Pashanov ED; Karachunskiy AI Ter Arkh; 2018 Aug; 90(7):38-50. PubMed ID: 30701921 [TBL] [Abstract][Full Text] [Related]
32. The role of nelarabine in the treatment of T-cell acute lymphoblastic leukemia/lymphoma: challenges, opportunities, and future directions. Miller LH; Maxa KL; Winter SS; Gossai NP Expert Rev Anticancer Ther; 2023; 23(12):1229-1236. PubMed ID: 37850259 [TBL] [Abstract][Full Text] [Related]
33. Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T-cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study. Candoni A; Lazzarotto D; Ferrara F; Curti A; Lussana F; Papayannidis C; Del Principe MI; Bonifacio M; Mosna F; Delia M; Minetto P; Gottardi M; Fracchiolla N; Mancini V; Forghieri F; Zappasodi P; Cerrano M; Vitale A; Audisio E; Trappolini S; Romani C; Defina M; Imbergamo S; Ciccone N; Santoro L; Cambò B; Iaccarino S; Dargenio M; Aprile L; Chiaretti S; Fanin R; Pizzolo G; Foà R Am J Hematol; 2020 Dec; 95(12):1466-1472. PubMed ID: 32777149 [TBL] [Abstract][Full Text] [Related]
35. Phase I dose-escalation trial of clofarabine followed by escalating doses of fractionated cyclophosphamide in children with relapsed or refractory acute leukemias. Abd Elmoneim A; Gore L; Ricklis RM; Boklan J; Cooper T; Narendran A; Rolla K; Scott T; Arceci RJ Pediatr Blood Cancer; 2012 Dec; 59(7):1252-8. PubMed ID: 22887831 [TBL] [Abstract][Full Text] [Related]